Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.

Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.

The present invention provides compounds having the general formula (I) wherein R.sup.1 to R.sup.10, Gi, G.sub.2, X and m are as described herein, compositions including the compounds and methods of using the compounds for treating hepatitis B.

##STR00001##

The present invention provides compounds having the general formula (I) wherein R.sup.1 to R.sup.10, Gi, G.sub.2, X and m are as described herein, compositions including the compounds and methods of using the compounds for treating hepatitis B.

##STR00001##

The present application discloses derivatives of polyphenols, pharmaceutically acceptable salts, stereoisomers or tautomers thereof. The compounds and compositions described herein can be used in therapy.

The present application discloses derivatives of polyphenols, pharmaceutically acceptable salts, stereoisomers or tautomers thereof. The compounds and compositions described herein can be used in therapy.

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. ##STR00001##

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. ##STR00001##

A method for preparing a Hovenia dulcis Thunb extract rich in dihydromyricetin includes the following steps: (1) crushing Hovenia dulcis Thunb seeds to obtain a Hovenia dulcis Thunb powder; (2) adding a 10-95% ethanol solution in an amount of 3-15 times of an amount of the Hovenia dulcis Thunb powder, stirring and extracting at 20° C-80° C. twice; (3) filtering to obtain an extract solution; (4) concentrating the extract solution by evaporating ethanol under reduced pressure to obtain a crude extract, the crude extract having a solid content of 10%-40%; (5) placing the crude extract at −20° C. to 8° C. for 0.5 to 12 hours; (6) centrifuging the crude extract to obtain a supernatant; and (7) spray-drying the supernatant to obtain the Hovenia dulcis Thunb extract.

The invention relates to a method for directly producing morin derivatives and high-purity morin of formula (I). The invention also relates to morin derivatives and high-purity morin that can be obtained using the claimed method. ##STR00001##